HRP20230265T1 - Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima - Google Patents
Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima Download PDFInfo
- Publication number
- HRP20230265T1 HRP20230265T1 HRP20230265TT HRP20230265T HRP20230265T1 HR P20230265 T1 HRP20230265 T1 HR P20230265T1 HR P20230265T T HRP20230265T T HR P20230265TT HR P20230265 T HRP20230265 T HR P20230265T HR P20230265 T1 HRP20230265 T1 HR P20230265T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- administered
- antibody
- stem cell
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 31
- 208000034578 Multiple myelomas Diseases 0.000 title claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 2
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 238000011476 stem cell transplantation Methods 0.000 claims 6
- 208000007660 Residual Neoplasm Diseases 0.000 claims 4
- 238000009093 first-line therapy Methods 0.000 claims 4
- 229960001467 bortezomib Drugs 0.000 claims 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 229960002438 carfilzomib Drugs 0.000 claims 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 3
- 108010021331 carfilzomib Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000003207 proteasome inhibitor Substances 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Spoj za upotrebu u postupku liječenja multiplog mijeloma kod pacijenta koji ima multipli mijelom i koji je primio transplantaciju matičnih stanica,
naznačen time što spoj ima formulu:
[image]
ili njegova farmaceutski prihvatljiva sol, solvat, hidrat ili stereoizomer;
pri čemu je pacijent primio indukcijsku terapiju sa spojem prije transplantacije matičnih stanica; i
pri čemu postupak obuhvaća:
a. određivanje statusa minimalne rezidualne bolesti (MRD) pacijenta nakon transplantacije matičnih stanica; i
b. ako je status minimalne rezidualne bolesti (MRD) pacijenta veći od 0,01%, spoj se primjenjuje u količini od 1 do 50 mg dnevno u kombinaciji s terapeutski učinkovitom količinom anti-CS1 protutijela.
2. Spoj za upotrebu prema zahtjevu 1, naznačen time što je pacijent primio indukcijsku terapiju kombinacijom spoja i inhibitora proteasoma prije transplantacije matičnih stanica.
3. Spoj za upotrebu prema zahtjevu 1, naznačen time što je multipli mijelom recidivirajući, refraktorni, ili recidivirajući i refraktorni multipli mijelom.
4. Spoj za upotrebu prema zahtjevu 1, naznačen time što se spoj primjenjuje ciklički, po izboru pri čemu se spoj daje 21 dan nakon čega slijedi sedam dana odmora u ciklusu od 28 dana.
5. Spoj za upotrebu prema zahtjevu 1, naznačen time što se spoj primjenjuje u količini od 2,5 mg, 5 mg, 10 mg, 15 mg, 20 mg ili 25 mg dnevno.
6. Spoj za upotrebu prema zahtjevu 5, naznačen time što se spoj daje u kapsuli u količini od 25 mg.
7. Spoj za upotrebu prema zahtjevu 1, naznačen time što se spoj primjenjuje oralno.
8. Spoj za upotrebu prema zahtjevu 7, naznačen time što se spoj primjenjuje u obliku kapsule ili tablete; po izboru pri čemu kapsula sadrži spoj, bezvodnu laktozu, mikrokristalnu celulozu, kroskarmelozu natrij i magnezijev stearat.
9. Spoj za upotrebu prema zahtjevu 1, naznačen time što je anti-CS1 protutijelo monoklonsko protutijelo, izborno elotuzumab.
10. Spoj za upotrebu prema zahtjevu 9,
pri čemu se protutijelo primjenjuje intravenozno u količini od 1 do 1000 mg tjedno ili svaki drugi tjedan, po izboru pri čemu se protutijelo primjenjuje u količini od 10 mg/kg; ili
pri čemu se protutijelo primjenjuje tjedno ili svaki drugi tjedan; ili
pri čemu se protutijelo primjenjuje 1., 8., 15. i 22. dana u ciklusu od 28 dana; ili
pri čemu se protutijelo primjenjuje 1. i 15. dana u ciklusu od 28 dana.
11. Spoj za upotrebu prema zahtjevu 1,
naznačen time što je spoj
[image]
i nije njegova farmaceutski prihvatljiva sol, solvat, hidrat ili stereoizomer; ili
pri čemu je spoj farmaceutski prihvatljiva sol; ili
pri čemu je spoj farmaceutski prihvatljiv solvat.
12. Spoj za upotrebu prema zahtjevu 2, naznačen time što je inhibitor proteasoma bortezomib ili karfilzomib.
13. Spoj za upotrebu prema zahtjevu 12,
pri čemu je pacijent primio indukcijsku terapiju lenalidomidom u kombinaciji s bortezomibom ili karfilzomibom; ili
pri čemu je pacijent primio indukcijsku terapiju lenalidomidom u kombinaciji s bortezomibom ili karfilzomibom i deksametazonom.
14. Spoj za upotrebu prema zahtjevu 1, naznačen time što je transplantacija matičnih stanica autologna transplantacija matičnih stanica; ili transplantacija hematopoetskih matičnih stanica; ili transplantacija matičnih stanica periferne krvi.
15. Spoj za upotrebu prema zahtjevu 1, naznačen time što se spoj primjenjuje u kombinaciji s anti-CS1 protutijelom i deksametazonom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462040918P | 2014-08-22 | 2014-08-22 | |
PCT/US2015/046091 WO2016029004A1 (en) | 2014-08-22 | 2015-08-20 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
EP15757389.0A EP3182996B1 (en) | 2014-08-22 | 2015-08-20 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230265T1 true HRP20230265T1 (hr) | 2023-04-14 |
Family
ID=54035318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230265TT HRP20230265T1 (hr) | 2014-08-22 | 2015-08-20 | Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima |
Country Status (23)
Country | Link |
---|---|
US (1) | US10034872B2 (hr) |
EP (2) | EP3182996B1 (hr) |
JP (2) | JP7120763B2 (hr) |
KR (1) | KR20170042598A (hr) |
CN (1) | CN107073115A (hr) |
AU (2) | AU2015305449B2 (hr) |
BR (1) | BR112017003620A2 (hr) |
CA (1) | CA2958867A1 (hr) |
CL (1) | CL2017000416A1 (hr) |
DK (1) | DK3182996T3 (hr) |
EA (1) | EA201790439A1 (hr) |
ES (1) | ES2940302T3 (hr) |
FI (1) | FI3182996T3 (hr) |
HR (1) | HRP20230265T1 (hr) |
HU (1) | HUE061382T2 (hr) |
IL (1) | IL250724A0 (hr) |
LT (1) | LT3182996T (hr) |
MX (1) | MX2017002382A (hr) |
PL (1) | PL3182996T3 (hr) |
PT (1) | PT3182996T (hr) |
RS (1) | RS64038B1 (hr) |
SI (1) | SI3182996T1 (hr) |
WO (1) | WO2016029004A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3950065A1 (en) * | 2015-06-29 | 2022-02-09 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer |
CN110099907A (zh) | 2016-12-21 | 2019-08-06 | 拜欧赛里克斯公司 | 靶向蛋白质的噻吩并吡咯衍生物、组合物、方法及其用途 |
CN111132696B (zh) * | 2017-10-13 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 |
EP3807283A1 (en) * | 2018-06-13 | 2021-04-21 | Biotheryx, Inc. | Fused thiophene compounds |
EP3860610A4 (en) * | 2018-10-01 | 2022-06-15 | Celgene Corporation | POLYTHERAPY FOR THE TREATMENT OF CANCER |
WO2020102226A1 (en) * | 2018-11-13 | 2020-05-22 | Nantcell, Inc | Combination therapies for multiple myeloma |
WO2021119023A1 (en) * | 2019-12-08 | 2021-06-17 | The Regents Of The University Of Colorado, A Body Corporate | Multiple myeloma combination therapies based on protein translation inhibitors and immunomodulators |
EP4073517A1 (en) * | 2019-12-11 | 2022-10-19 | Erasmus University Rotterdam Medical Center | Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias |
WO2022072538A1 (en) * | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2023014082A1 (ko) * | 2021-08-04 | 2023-02-09 | 주식회사 아이비스바이오 | 물질 특성이 개선된 면역조절아마이드 유도체 |
KR102362871B1 (ko) * | 2021-11-19 | 2022-02-15 | 케이블루바이오 주식회사 | 신규한 사환구조 트리테르펜 화합물을 유효성분으로 포함하는 다발성골수종의 예방 또는 치료용 조성물 |
Family Cites Families (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL294688A (hr) | 1961-04-26 | |||
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4551177A (en) | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5974203A (en) | 1988-04-11 | 1999-10-26 | Canon Kabushiki Kaisha | Pattern recognition communication apparatus for transmitting and receiving image data |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
EP0505552A4 (en) | 1990-10-12 | 1994-06-08 | Amgen Inc | Megakaryocyte maturation factors |
US5387421A (en) | 1991-01-31 | 1995-02-07 | Tsrl, Inc. | Multi stage drug delivery system |
WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US20010056114A1 (en) | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US5594637A (en) | 1993-05-26 | 1997-01-14 | Base Ten Systems, Inc. | System and method for assessing medical risk |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5641758A (en) | 1993-11-10 | 1997-06-24 | Kluge; Michael | Cytarabine derivatives, the preparation and use thereof |
US6432924B1 (en) | 1993-12-26 | 2002-08-13 | East Carolina University | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
WO1996013790A1 (en) | 1994-10-28 | 1996-05-09 | Advanced Health Med-E-Systems Corporation | Prescription management system |
US5593696A (en) | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
US5619991A (en) | 1995-04-26 | 1997-04-15 | Lucent Technologies Inc. | Delivery of medical services using electronic data communications |
US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5832449A (en) | 1995-11-13 | 1998-11-03 | Cunningham; David W. | Method and system for dispensing, tracking and managing pharmaceutical trial products |
US6063026A (en) | 1995-12-07 | 2000-05-16 | Carbon Based Corporation | Medical diagnostic analysis system |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
DK0925294T6 (da) | 1996-07-24 | 2018-08-20 | Celgene Corp | Substituerede 2-(2,6-dioxopiperidin-3-yl)phthalimider og -1-oxoisoindoliner samt fremgangsmåde til reduktion af tnf-alpha-niveauer |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
ATE236872T1 (de) | 1996-08-12 | 2003-04-15 | Celgene Corp | Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte |
US5924074A (en) | 1996-09-27 | 1999-07-13 | Azron Incorporated | Electronic medical records system |
DK1586322T3 (da) | 1996-11-05 | 2008-12-01 | Childrens Medical Center | Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer |
US6131090A (en) | 1997-03-04 | 2000-10-10 | Pitney Bowes Inc. | Method and system for providing controlled access to information stored on a portable recording medium |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
PT998271E (pt) | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
AU8909898A (en) | 1997-08-22 | 1999-03-16 | Deka Products Limited Partnership | Health care system and method for physician order entry |
US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
US6096757A (en) | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
KR100712573B1 (ko) | 1998-03-16 | 2007-05-02 | 셀진 코포레이션 | 염증성 사이토카인 억제제용 2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그 제조방법 및 그 용도 |
JPH11286455A (ja) | 1998-03-31 | 1999-10-19 | Kanebo Ltd | 骨髄異形成症候群治療薬 |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US20030013739A1 (en) | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
GB9904585D0 (en) | 1999-02-26 | 1999-04-21 | Gemini Research Limited | Clinical and diagnostic database |
HUP0200499A3 (en) | 1999-03-18 | 2002-12-28 | Celgene Corp Warren | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use for preparation of pharmaceutical compositions for reducing inflammatory cytokine levels |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6890547B1 (en) | 1999-07-16 | 2005-05-10 | Amato Pharmaceutical Products, Ltd. | Glycyrrhizin preparations for transmucosal absorption |
US6202923B1 (en) | 1999-08-23 | 2001-03-20 | Innovation Associates, Inc. | Automated pharmacy |
US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
CA2319872C (en) | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
EP1267939A2 (en) | 2000-03-17 | 2003-01-02 | Cell Therapeutics, Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
CA2404152C (en) | 2000-03-31 | 2008-08-05 | Celgene Corporation | Inhibition of cyclooxygenase-2 activity |
EP1286671B1 (en) | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
WO2001087307A2 (en) | 2000-05-15 | 2001-11-22 | Celgene Corp. | Compositions and methods for the treatment of cancer |
AU2001280161A1 (en) | 2000-08-24 | 2002-03-04 | Kirin Beer Kabushiki Kaisha | C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes |
US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
AU2002253795B2 (en) | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
US20020128228A1 (en) | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
DE60231989D1 (de) | 2001-08-06 | 2009-05-28 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
JP4027693B2 (ja) | 2002-03-20 | 2007-12-26 | トリニティ工業株式会社 | 塗料送給装置及びバルブユニット |
US20030220254A1 (en) | 2002-03-29 | 2003-11-27 | Texas Tech University System | Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1496878A4 (en) | 2002-04-12 | 2007-12-26 | Celgene Corp | TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS |
NZ563281A (en) | 2002-05-17 | 2009-05-31 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
NZ536908A (en) | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404717B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
AU2003286836A1 (en) | 2002-10-31 | 2004-06-07 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
US20040152632A1 (en) | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
CL2004001004A1 (es) | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
JP2007532642A (ja) | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物 |
AU2004319758A1 (en) | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20070155791A1 (en) | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
SI2068874T1 (sl) * | 2006-08-07 | 2015-06-30 | Abbvie Biotherapeutics Inc. | Postopki zdravljenja multiplega mieloma z uporabo kombinacijske terapije utemeljene na anti-csi protitelesih |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
US8664272B2 (en) | 2006-08-30 | 2014-03-04 | Temple University—Of the Commonwealth System of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
ME02420B (me) | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
ES2523925T3 (es) | 2007-09-26 | 2014-12-02 | Celgene Corporation | Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos |
JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
CA2742252A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
EP3692983B1 (en) | 2008-05-15 | 2021-08-11 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
KR101696938B1 (ko) | 2008-10-29 | 2017-01-16 | 셀진 코포레이션 | 암의 치료에 사용하기 위한 이소인돌린 화합물 |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
KR101381060B1 (ko) | 2009-05-19 | 2014-04-11 | 셀진 코포레이션 | 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온의 제제 |
UA114856C2 (uk) | 2010-02-11 | 2017-08-10 | Селджин Корпорейшн | Способи лікування із застосуванням похідних арилметоксіізоіндоліну |
DK2683384T3 (da) | 2011-03-11 | 2016-02-08 | Celgene Corp | Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion |
US20140142128A1 (en) | 2012-11-20 | 2014-05-22 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
US20180021378A1 (en) * | 2014-12-31 | 2018-01-25 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
EP3950065A1 (en) * | 2015-06-29 | 2022-02-09 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer |
-
2015
- 2015-08-20 HR HRP20230265TT patent/HRP20230265T1/hr unknown
- 2015-08-20 EP EP15757389.0A patent/EP3182996B1/en active Active
- 2015-08-20 JP JP2017510546A patent/JP7120763B2/ja active Active
- 2015-08-20 LT LTEPPCT/US2015/046091T patent/LT3182996T/lt unknown
- 2015-08-20 BR BR112017003620A patent/BR112017003620A2/pt not_active Application Discontinuation
- 2015-08-20 RS RS20230191A patent/RS64038B1/sr unknown
- 2015-08-20 KR KR1020177004321A patent/KR20170042598A/ko not_active Application Discontinuation
- 2015-08-20 SI SI201531929T patent/SI3182996T1/sl unknown
- 2015-08-20 DK DK15757389.0T patent/DK3182996T3/da active
- 2015-08-20 HU HUE15757389A patent/HUE061382T2/hu unknown
- 2015-08-20 FI FIEP15757389.0T patent/FI3182996T3/fi active
- 2015-08-20 PT PT157573890T patent/PT3182996T/pt unknown
- 2015-08-20 AU AU2015305449A patent/AU2015305449B2/en active Active
- 2015-08-20 MX MX2017002382A patent/MX2017002382A/es unknown
- 2015-08-20 PL PL15757389.0T patent/PL3182996T3/pl unknown
- 2015-08-20 ES ES15757389T patent/ES2940302T3/es active Active
- 2015-08-20 EP EP21172501.5A patent/EP3925609A1/en active Pending
- 2015-08-20 CA CA2958867A patent/CA2958867A1/en not_active Abandoned
- 2015-08-20 US US14/831,616 patent/US10034872B2/en active Active
- 2015-08-20 WO PCT/US2015/046091 patent/WO2016029004A1/en active Application Filing
- 2015-08-20 EA EA201790439A patent/EA201790439A1/ru unknown
- 2015-08-20 CN CN201580056904.9A patent/CN107073115A/zh not_active Withdrawn
-
2017
- 2017-02-20 CL CL2017000416A patent/CL2017000416A1/es unknown
- 2017-02-22 IL IL250724A patent/IL250724A0/en unknown
-
2020
- 2020-10-01 JP JP2020166647A patent/JP2021006557A/ja active Pending
-
2021
- 2021-07-26 AU AU2021209158A patent/AU2021209158A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2017525713A (ja) | 2017-09-07 |
AU2015305449B2 (en) | 2021-05-06 |
PL3182996T3 (pl) | 2023-04-17 |
EP3182996B1 (en) | 2022-12-28 |
US10034872B2 (en) | 2018-07-31 |
CA2958867A1 (en) | 2016-02-25 |
RS64038B1 (sr) | 2023-04-28 |
US20160051530A1 (en) | 2016-02-25 |
BR112017003620A2 (pt) | 2017-12-05 |
SI3182996T1 (sl) | 2023-04-28 |
EP3925609A1 (en) | 2021-12-22 |
JP2021006557A (ja) | 2021-01-21 |
IL250724A0 (en) | 2017-04-30 |
LT3182996T (lt) | 2023-03-10 |
KR20170042598A (ko) | 2017-04-19 |
JP7120763B2 (ja) | 2022-08-17 |
EA201790439A1 (ru) | 2017-07-31 |
PT3182996T (pt) | 2023-03-21 |
AU2021209158A1 (en) | 2021-08-19 |
ES2940302T3 (es) | 2023-05-05 |
EP3182996A1 (en) | 2017-06-28 |
HUE061382T2 (hu) | 2023-06-28 |
CL2017000416A1 (es) | 2017-09-08 |
DK3182996T3 (da) | 2023-03-13 |
CN107073115A (zh) | 2017-08-18 |
FI3182996T3 (fi) | 2023-03-28 |
MX2017002382A (es) | 2017-05-17 |
WO2016029004A1 (en) | 2016-02-25 |
AU2015305449A1 (en) | 2017-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230265T1 (hr) | Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima | |
JP2017525713A5 (hr) | ||
JP2015187156A5 (hr) | ||
JP2017048208A5 (hr) | ||
JP2018506550A5 (hr) | ||
HRP20161284T1 (hr) | METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM | |
JP2015038135A5 (hr) | ||
PH12019501811A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
PH12018501237A1 (en) | Isoindole compounds | |
RU2013148590A (ru) | Способы введения антагонистов интегрина бета7 | |
RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
PH12021500012A1 (en) | Inhibitors of keapi-nrf2 protein-protein interaction | |
RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
IL292655A (en) | Combined therapy of c-c cytokine receptor type 9 (ccr9) inhibitors and integrin-blocking anti-alha4beta7 antibodies | |
HRP20201632T4 (hr) | Režimi doziranja melflufena kod raka | |
JP2016516692A5 (hr) | ||
PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
JP2017530163A5 (hr) | ||
MX2017014396A (es) | Tratamiento de mieloma multiple. | |
JP2017524652A5 (hr) | ||
EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
JP2019515003A5 (hr) | ||
PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
Zangari et al. | Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo |